Emanuel F. Petricoin

University of North Carolina at Chapel Hill — United States

Chemistry · Physical Sciences

81h-index27.9kcitations626works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Proteomics Techniques and Applications(125), Advanced Biosensing Techniques and Applications(104), Monoclonal and Polyclonal Antibodies Research(78), Cancer Genomics and Diagnostics(76), HER2/EGFR in Cancer Research(61)

Publications624 total

Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance
2025Open Access
Abstract C051: Emerging Novel Targets to treat non-responding HER2-negative breast cancer patients: The neoadjuvant I-SPY2 TRIAL 2300 patient Omics data and organoid studies
Molecular Cancer Therapeutics·2025
Proteogenomic characterization of invasive breast tumors in young women
npj Breast Cancer·2025· 3 citedOpen Access
Evaluating the Effect of <i>KRAS</i> Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer
JCO Precision Oncology·2025· 2 citedOpen Access
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
UNC Libraries·2025Open Access
RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling
UNC Libraries·2025Open Access
Editorial: Clinical implementation of precision oncology data to direct individualized and immunotherapy-based treatment strategies
Frontiers in Immunology·2025· 1 citedOpen Access
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
JCO Precision Oncology·2025· 4 citedOpen Access
Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC).
Journal of Clinical Oncology·2025· 2 cited
Actionability landscape and biomarker utility in a colorectal cancer alliance cohort: Initial results from the Know Your Biomarker program.
Journal of Clinical Oncology·2025
Abstract 5762: RPPA kinomic profiling of a tumor eradication phenotype induced by SIAH inhibition, a major tumor vulnerability in the EGFR/HER2/RAS signaling pathway, in late-stage and metastatic human cancer cell lines
Cancer Research·2025
Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boards
npj Precision Oncology·2025· 1 citedOpen Access
The EGFR Pathway as a Potential Therapeutic Target for Modulation of Radiation-induced Liver Injury
Radiation Research·2025· 1 cited
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
Cell Reports Medicine·2024· 6 citedOpen Access
Integrating Functional Protein Drug Target Data into a Precision Oncology Molecular Tumor Board
2024Open Access
Clinical outcomes of gynecologic tumor treatment correlate with ERK protein phosphorylation as measured by a CLIA-accredited phosphoprotein assay
Gynecologic Oncology·2024
296 (PB284): EZH2 is a druggable target of resistance to CDK4/6 inhibitors in breast cancer
European Journal of Cancer·2024
Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort
British Journal of Cancer·2024· 6 citedOpen Access
Association Between Testosterone Reactivity and Maximal Physical Performance: Pilot Study
Medicine & Science in Sports & Exercise·2024
Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer
npj Precision Oncology·2024· 7 citedOpen Access
page 1 of 32Next →

Frequent Co-authors

Lance A. Liotta(30), Julia Wulfkuhle(7), Virginia Espina(7), John W. Gillespie(6), Cloud P. Paweletz(6), Michael R. Emmert‐Buck(5), David K. Ornstein(5), David A. Fishman(4), Elise C. Kohn(4), Yingming Zhao(4), Ben A. Hitt(3), Vincent A. Fusaro(3), Sally Ross(3), Thomas P. Conrads(3), Timothy D. Veenstra(3), Kirsten L. Bryant(3), Mariaelena Pierobon(3), Adrienne D. Cox(3), Channing J. Der(3), Jonathan R. Brody(3)